Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25832913 | 0.87 | TSHR (0.43) | TSHRRECQLGLP1REPHX2MAPT | |
| SCHEMBL25123586 | 0.84 | TSHR (0.40) | TSHRRECQLGLP1REPHX2MAPT | |
| SCHEMBL25110641 | 0.83 | TSHR (0.48) | TSHRRECQLGLP1REPHX2MAPT | |
| SCHEMBL23945966 | 0.77 | TSHR (0.36) | TSHRRECQLGLP1REPHX2MAPT | |
| SCHEMBL22473620 | 0.77 | GLP1R (0.43) | TSHRRECQLGLP1REPHX2FAAH | |
| SCHEMBL26373835 | 0.76 | MMP9 (0.41) | TSHRRECQLGLP1REPHX2MAPT | |
| SCHEMBL25832916 | 0.75 | TSHR (0.47) | TSHRRECQLGLP1RMAPTHSD17B10 | |
| SCHEMBL25123197 | 0.75 | TSHR (0.47) | TSHRRECQLGLP1RMAPTHSD17B10 | |
| SCHEMBL25122630 | 0.75 | TSHR (0.47) | TSHRRECQLGLP1RMAPTHSD17B10 | |
| SCHEMBL25729686 | 0.75 | EPHX2 (0.43) | TSHRRECQLGLP1REPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885RECQL 2866/4885GLP1R 2955/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885RECQL 2866/4885GLP1R 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.